Fluoropharma Medical, developer of advanced medical diagnostic imaging products, sees an open-ended range of potential markets in its future, since many of the possibilities related to the advanced imaging technologies on which the company is focused have only begun to be explored.
FluoroPharma’s products support the fast growing PET (positron emission tomography) industry, a branch of nuclear medicine that produces a 3D image of previously hidden biological processes occurring within the body. Unlike most imaging tools, designed to reveal various structures inside the body, PET technology reveals processes at the cellular and even molecular level, providing a unique insight into potential diseases at the very earliest stages. Specifically, FluoroPharma develops critical molecular imaging agents that give PET the ability to track and register targeted processes. Today the market for molecular imaging agents exceeds $1.7 billion annually.
FluoroPharma’s immediate focus is on imaging agents used for the detection of acute and chronic forms of coronary artery disease (NYSEARCA:CAD). Coronary artery disease affects more than 13 million patients in the U.S. alone, accounting for more than 30% of all deaths. The current need is for faster and more accurate diagnostic tools for the detection and assessment of acute and chronic CAD. Molecular imaging is currently used in more than 9 million myocardial perfusion imaging (MPI) procedures, the standard test for diagnosing CAD.
But there are now a number of other emerging opportunities for the application of PET technology. A good example is Alzheimer’s disease, already afflicting over 5 million Americans, with cases expected to grow dramatically as the population ages. Right now there is no single diagnostic test to confirm that a person even has Alzheimer’s. FluoroPharma is developing new options for early detection and treatment of the disease to improve patient care and create new paths for its management. In addition, the company is coming up with new compounds to enable the early and accurate diagnosis of prostate cancer, the most frequently diagnosed and most lethal malignancy among men in the U.S.
FluoroPharma’s broad technology platform was developed by scientists at the Massachusetts General Hospital and Harvard Medical School. The company has four issued U.S. patents, with seven pending applications, together with strong international protection. FluoroPharma also pursues opportunities to license new PET technologies from individuals and institutions.
For more information, see the company website at www.FluoroPharma.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html